CLNN · Clene Inc.

This 8-K represents a pivotal regulatory inflection point for Clene: the FDA has formally indicated that Clene’s existing clinical and biomarker dataset — centered on reductions in plasma neurofilament light (NfL) — may be sufficient to support an accelerated approval NDA for CNM-Au8 in ALS. Critically, the Agency did not require new efficacy endpoints or additional Phase 3 data prior to submission; instead, it affirmed NfL’s potential qualification as a surrogate endpoint reasonably likely to predict clinical benefit, per 21 CFR 314.510. The planned Q3 2026 NDA submission is explicitly anchored to data already generated — including NfL changes correlated with longer survival in the open-label extension of the HEALEY trial, plus results from RESCUE-ALS and the NIH Expanded Access Protocol — rather than pending studies. While the FDA requested supplemental analyses linking the magnitude of NfL reduction to clinical benefit, Clene states those materials are prepared and will be included. The commitment to launch a confirmatory Phase 3 trial in Q1 2027 reflects standard post-accelerated-approval obligations, not a condition precedent to filing. For investors, this shifts Clene’s near-term risk profile from 'will the FDA accept the pathway?' to 'will the NDA be accepted for review, and ultimately approved, based on the submitted biomarker-clinical package?' Given ALS’s rapid progression and lack of disease-modifying therapies, successful accelerated approval would represent a major commercial and clinical milestone — especially as CNM-Au8 is positioned as a first-in-class mitochondrial therapy with orphan designation. The absence of disclosed financial metrics, earnings, or capital events further underscores that the materiality resides entirely in this de-risked regulatory pathway forward.